Regeneron Pharmaceuticals
Regeneron Pharmaceuticals returns on capital
Annual and trailing 12-month returns on invested capital, equity and assets.
ROIC
% · Annual / TTM
Reported borrowing balances are unavailable in the extracted statements for this period.
ROCE
% · Annual / TTM
ROIIC
% · Annual / TTM
Reported borrowing balances are unavailable in the extracted statements for this period.
ROE
% · Annual / TTM
ROA
% · Annual / TTM
ROIC − WACC
Percentage points · Scenario
Reported borrowing balances are unavailable in the extracted statements for this period.
Quarterly data
| Fiscal period | Ended | ROIC% | ROCE% | ROIIC% | ROE% | ROA% | ROIC − WACCPercentage points |
|---|---|---|---|---|---|---|---|
| FY 2026 Q2 | Jun 30, 2026 | — | 10.86% | — | 14.04% | 10.83% | — |
| FY 2026 Q1 | Mar 31, 2026 | — | 10.41% | — | 14.55% | 11.28% | — |
| FY 2025 Q4 | Dec 31, 2025 | — | 10.22% | — | 14.87% | 11.5% | — |
| FY 2025 Q3 | Sep 30, 2025 | — | 10.61% | — | 15.19% | 11.8% | — |
| FY 2025 Q2 | Jun 30, 2025 | — | 11.44% | — | 15.34% | 12% | — |
| FY 2025 Q1 | Mar 31, 2025 | — | 11.83% | — | 15.96% | 12.51% | — |
| FY 2024 Q4 | Dec 31, 2024 | — | 12.57% | — | 15.95% | 12.46% | — |
| FY 2024 Q3 | Sep 30, 2024 | — | 12.75% | — | 17.17% | 13.37% | — |
| FY 2024 Q2 | Jun 30, 2024 | — | 12.99% | — | 16.55% | 12.95% | — |
| FY 2024 Q1 | Mar 31, 2024 | — | 13.34% | — | 15.28% | 11.98% | — |
| FY 2023 Q4 | Dec 31, 2023 | — | 14.52% | — | 16.26% | 12.69% | — |
| FY 2023 Q3 | Sep 30, 2023 | — | 15.82% | — | 17.22% | 13.34% | — |
| FY 2023 Q2 | Jun 30, 2023 | — | 16.76% | — | 19.23% | 14.86% | — |
| FY 2023 Q1 | Mar 31, 2023 | — | 17.6% | — | 19.27% | 14.83% | — |
| FY 2022 Q4 | Dec 31, 2022 | — | 19.92% | — | 20.94% | 15.88% | — |
| FY 2022 Q3 | Sep 30, 2022 | — | 27.85% | — | 27.76% | 20.92% | — |
| FY 2022 Q2 | Jun 30, 2022 | — | 32.7% | — | 31.76% | 23.36% | — |
| FY 2022 Q1 | Mar 31, 2022 | — | 47.99% | — | 49.75% | 35.96% | — |
| FY 2021 Q4 | Dec 31, 2021 | — | 49.75% | — | 54.21% | 37.91% | — |
| FY 2021 Q3 | Sep 30, 2021 | — | 44.35% | — | 51.09% | 35.19% | — |
| FY 2021 Q2 | Jun 30, 2021 | — | 46.91% | — | 51.32% | 34.56% | — |
| FY 2021 Q1 | Mar 31, 2021 | — | 28.24% | — | 33.21% | 23.88% | — |
| FY 2020 Q4 | Dec 31, 2020 | — | 26.32% | — | 31.77% | 21.98% | — |
| FY 2020 Q3 | Sep 30, 2020 | — | 23.81% | — | 30.6% | 21.02% | — |
| FY 2020 Q2 | Jun 30, 2020 | — | 24.98% | — | 31.72% | 21.62% | — |
| FY 2020 Q1 | Mar 31, 2020 | — | 19.4% | — | 21.13% | 15.93% | — |
| FY 2019 Q4 | Dec 31, 2019 | — | 19.22% | — | 21.32% | 15.94% | — |
| FY 2019 Q3 | Sep 30, 2019 | — | 20.89% | — | 23.34% | 17.33% | — |
| FY 2019 Q2 | Jun 30, 2019 | — | 21.32% | — | 24.43% | 17.9% | — |
| FY 2019 Q1 | Mar 31, 2019 | — | 25.16% | — | 30.32% | 21.84% | — |
| FY 2018 Q4 | Dec 31, 2018 | — | 28.28% | — | 32.81% | 23.85% | — |
| FY 2018 Q3 | Sep 30, 2018 | — | 27.79% | — | 25.83% | 18.43% | — |
| FY 2018 Q2 | Jun 30, 2018 | — | 29.15% | — | 25.04% | 17.62% | — |
| FY 2018 Q1 | Mar 31, 2018 | — | 30.33% | — | 24.97% | 16.61% | — |
| FY 2017 Q4 | Dec 31, 2017 | — | 31.13% | — | 22.63% | 15.23% | — |
| FY 2017 Q3 | Sep 30, 2017 | — | 28.11% | — | 24.25% | 16.46% | — |
| FY 2017 Q2 | Jun 30, 2017 | — | 27.42% | — | 24.06% | 16.14% | — |
| FY 2017 Q1 | Mar 31, 2017 | — | 24.92% | — | 22.32% | 14.04% | — |
| FY 2016 Q4 | Dec 31, 2016 | — | 25.28% | — | 22.1% | 14.23% | — |
| FY 2016 Q3 | Sep 30, 2016 | — | 23.55% | — | 20.08% | 13.02% | — |
| FY 2016 Q2 | Jun 30, 2016 | — | 27.12% | — | 19.62% | 13.55% | — |
| FY 2016 Q1 | Mar 31, 2016 | — | 30.01% | — | 21.55% | 14.37% | — |
| FY 2015 Q4 | Dec 31, 2015 | — | 31.24% | — | 20.53% | 13.42% | — |
| FY 2015 Q3 | Sep 30, 2015 | — | 31.8% | — | 20.22% | 13.25% | — |
| FY 2015 Q2 | Jun 30, 2015 | — | 29.22% | — | 16.14% | 11.54% | — |
| FY 2015 Q1 | Mar 31, 2015 | — | 27.33% | — | 13.84% | 9.62% | — |
| FY 2014 Q4 | Dec 31, 2014 | — | 28.08% | — | 15.05% | 9.91% | — |
| FY 2014 Q3 | Sep 30, 2014 | — | 28.18% | — | 15.78% | 10.49% | — |
| FY 2014 Q2 | Jun 30, 2014 | — | 32.48% | — | 20.52% | 13.58% | — |
| FY 2014 Q1 | Mar 31, 2014 | — | 31.5% | — | 21.61% | 14.12% | — |
| FY 2013 Q4 | Dec 31, 2013 | — | 33.27% | — | 26.54% | 16.87% | — |
| FY 2013 Q3 | Sep 30, 2013 | — | 36% | — | 63.93% | 37.11% | — |
| FY 2013 Q2 | Jun 30, 2013 | — | 38.23% | — | 81.24% | 44.22% | — |
| FY 2013 Q1 | Mar 31, 2013 | — | 36.01% | — | 87.68% | 46.19% | — |
| FY 2012 Q4 | Dec 31, 2012 | — | 29.6% | — | 86.68% | 44.08% | — |
| FY 2012 Q3 | Sep 30, 2012 | — | 22.87% | — | 36.69% | 17.13% | — |
| FY 2012 Q2 | Jun 30, 2012 | — | 0.53% | — | -5.11% | -2.19% | — |
| FY 2012 Q1 | Mar 31, 2012 | — | -13.2% | — | -32.61% | -13.75% | — |
| FY 2011 Q4 | Dec 31, 2011 | — | -19.03% | — | -43.76% | -18.38% | — |
| FY 2011 Q3 | Sep 30, 2011 | — | -20.81% | — | -47.12% | -19% | — |
| FY 2011 Q2 | Jun 30, 2011 | — | -18.48% | — | -36.37% | -16.81% | — |
| FY 2011 Q1 | Mar 31, 2011 | — | — | — | — | — | — |
| FY 2010 Q4 | Dec 31, 2010 | — | — | — | — | — | — |
| FY 2010 Q3 | Sep 30, 2010 | — | — | — | — | — | — |
| FY 2010 Q2 | Jun 30, 2010 | — | — | — | — | — | — |
Sources and calculations
Financial inputs from company filings. Last checked Oct 18, 2026. A dash means missing inputs or an undefined calculation.
Period changes use the preceding fiscal quarter or year. Percentage changes divide by the absolute prior value; a zero or missing baseline has no percentage change. Percentage metrics show changes in percentage points.
Quarterly returns use trailing 12-month earnings and period-end balances averaged with the same fiscal quarter one year earlier. NOPAT uses the reported effective tax rate only when pretax profit is positive and the rate is between 0 and 100%. WACC starts at 7.9%, rounded from the Pharmaceuticals benchmark in NYU Stern · January 2026. It is an editable US sector proxy applied across history, not a company estimate; foreign reporting currencies also need a currency-specific assessment.
Market prices: Yahoo Finance · REGN, USD. Latest completed close Sep 25, 2026. Price data retrieved Sep 28, 2026.
- ROIC
- NOPAT / average invested capital × 100. NOPAT = operating income × (1 − effective tax rate). Invested capital = equity including noncontrolling interests + debt − cash and equivalents. Average uses period end and one year earlier.
- ROCE
- Operating income / average (assets − current liabilities) × 100, using period end and one year earlier.
- ROIIC
- Year-over-year change in annual/TTM NOPAT / positive year-over-year change in invested capital × 100. Capital reductions and missing inputs yield unavailable values.
- ROE
- Earnings attributable to owners / average equity attributable to owners × 100, using period end and one year earlier.
- ROA
- Net income / average total assets × 100, using period end and one year earlier.
- ROIC − WACC
- ROIC less your WACC assumption, in percentage points. The same scenario rate is applied across history; it is not a reported or historical company WACC.